<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04943068</url>
  </required_header>
  <id_info>
    <org_study_id>KD-BMT-301</org_study_id>
    <nct_id>NCT04943068</nct_id>
  </id_info>
  <brief_title>A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)</brief_title>
  <official_title>A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kwang Dong Pharmaceutical co., ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kwang Dong Pharmaceutical co., ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to Evaluate the Efficacy and Safety of Subcutaneously&#xD;
      Administered Bremelanotide in Premenopausal Women with Hypoactive Sexual Desire Disorder(with&#xD;
      or without Decreased Arousal).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to End of Study in the desire domain from the FSFI</measure>
    <time_frame>Baseline up to End of Study(8weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to End of Study in FSDS-DAO (Item 13)</measure>
    <time_frame>Baseline up to End of Study(8weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to End of Study in the Number of Satisfying Sexual Events (SSEs) Associated With Study Drug Administration</measure>
    <time_frame>Baseline up to End of Study(8weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to End of Study in Mean Desire Score (Q3) From FSEP-R</measure>
    <time_frame>Baseline up to End of Study(8weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to End of Study in Mean Satisfaction With Desire Score (Q4) From FSEP-R</measure>
    <time_frame>Baseline up to End of Study(8weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to End of Study in the FSDS-DAO Total Score</measure>
    <time_frame>Baseline up to End of Study(8weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to End of study in the total FSFI score based on the 19 questions</measure>
    <time_frame>Baseline up to End of Study(8weeks)</time_frame>
    <description>The FSFI total score is on a scale ranging from 2 to 36. Increasing scores on this scale represent an increase in sexual desire and is a positive outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean Level of Sexual Arousal from FSEP-R Q6</measure>
    <time_frame>Baseline up to End of Study(8weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean Satisfaction with Sexual Arousal from FSEP-R Q7.</measure>
    <time_frame>Baseline up to End of Study(8weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to End of study in the scored time spent being concerned by difficulty with sexual arousal as measured by the FSDS-DAO Q14.</measure>
    <time_frame>Baseline up to End of Study(8weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to End of study in the arousal domain from the FSFI Q3 through Q6.</measure>
    <time_frame>Baseline up to End of Study(8weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to End of study in the total number of SSEs.</measure>
    <time_frame>Baseline up to End of Study(8weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the desire domain from the FSFI Q1 and Q2 using all available double-blind data (visit 4, 5)</measure>
    <time_frame>Baseline up to End of Study(8weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the score for feeling bothered by low sexual desire as measured by the FSDS -DAO Q13 using all available double-blind data(visit 4, 5)</measure>
    <time_frame>Baseline up to End of Study(8weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the number of SSEs associated with study drug using the entire 8 weeks of the double-blind phase.</measure>
    <time_frame>Baseline up to End of Study(8weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Hypoactive Sexual Desire Disorder</condition>
  <arm_group>
    <arm_group_label>Bremelanotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bremelanotide (BMT) subcutaneously (SC) via auto-injector for 8-weeks double-Blind period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo subcutaneously (SC) via auto-injector for 4-weeks single-Blind period and for 8-weeks double-Blind period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bremelanotide</intervention_name>
    <description>Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector.</description>
    <arm_group_label>Bremelanotide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will self-administer a Placebo subcutaneously (SC) via auto-injector.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        [Main Inclusion Criteria]&#xD;
&#xD;
          -  Has met diagnostic criteria for HSDD for at least 6 months&#xD;
&#xD;
          -  Is willing and able to understand and comply with all study requirements&#xD;
&#xD;
          -  Has a normal pelvic examination at screening&#xD;
&#xD;
        [Main Exclusion Criteria]&#xD;
&#xD;
          -  Subjects should be generally healthy premenopausal females with no psychological,&#xD;
             gynecological or urological conditions which might contribute to the sexual&#xD;
             dysfunction, compromise study participation, or confound interpretation of the study&#xD;
             results&#xD;
&#xD;
          -  Not currently under treatment for the sexual dysfunction and willing to forego other&#xD;
             treatments through the course of the clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soo Woong Kim, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tak Kim, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 10, 2021</study_first_submitted>
  <study_first_submitted_qc>June 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>June 20, 2021</last_update_submitted>
  <last_update_submitted_qc>June 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>KD-BMT-301</keyword>
  <keyword>Bremelanotide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypokinesia</mesh_term>
    <mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

